- £48.40m
- £36.73m
- £2.19m
REG - Angle PLC - Retail Offer via PrimaryBid
AnnouncementREG - Angle PLC - Issue of Equity
AnnouncementREG - Angle PLC - Result of 2022 Annual General Meeting
AnnouncementRCS - Angle PLC - Spread of breast cancer accelerates during sleep
AnnouncementREG - Angle PLC - Issue of Equity
AnnouncementREG - Angle PLC - Secured contract from pharma services customer
AnnouncementRCS - Angle PLC - Predicting immunotherapy response in SCLC
AnnouncementRCS - Angle PLC - Potential role of invasive cellular protrusions
AnnouncementREG - Angle PLC - Partnership with major United States urology group
AnnouncementRCS - Angle PLC - Molecular characterisation of CTCs
AnnouncementREG - Angle PLC - Price Monitoring Extension
AnnouncementREG - Angle PLC - ANGLE receives FDA clearance for Parsortix
AnnouncementRCS - Angle PLC - Prostate Cancer UK funds new study using Parsortix
AnnouncementREG - Angle PLC - Preliminary Results
AnnouncementREG - Angle PLC - Notice of Preliminary Results and Webcast
AnnouncementRCS - Angle PLC - Poster on Parsortix system presented at AACR 2022
AnnouncementRCS - Angle PLC - Identifying drug targets in cancer metastasis
AnnouncementRCS - Angle PLC - Rapid information on patient response to therapies
AnnouncementRCS - Angle PLC - Identifying therapeutic targets in TNBC patients
Announcement